Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Maxygen, Roche interferon deal

Roche (SWX:ROCZ) licensed worldwide rights to MAXY's next-generation interferon alpha and beta compounds to treat

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE